Research Paper

PAIN®

Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation reduces the development of long-term muscle pain

David A. Seminowicz[a,b,*], Enrico de Martino[c], Siobhan M. Schabrun[d], Thomas Graven-Nielsen[c]

Abstract

The left dorsolateral prefrontal cortex (DLPFC) is involved in the experience and modulation of pain, and may be an important node linking pain and cognition. Repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC can reduce chronic and experimental pain. However, whether left DLPFC rTMS can influence the development of chronic pain is unknown. Using repeated intramuscular injection of nerve growth factor to induce the development of sustained muscle pain (lasting weeks), 30 healthy individuals were randomized to receive 5 consecutive daily treatments of active or sham left DLPFC rTMS, starting before the first nerve growth factor injection on day 0. Muscle soreness and pain severity were collected daily for 14 days and disability on every alternate day. Before the first and 1 day after the last rTMS session, anxiety, depression, affect, pain catastrophizing, and cognitive performance on the attention network test were assessed. Left DLPFC rTMS treatment compared with sham was associated with reduced muscle soreness, pain intensity, and painful area ($P < 0.05$), and a similar trend was observed for disability. These effects were most evident during the days rTMS was applied lasting up to 3 days after intervention. Depression, anxiety, pain catastrophizing, and affect were unchanged. There was a trend toward improved cognitive function with rTMS compared with sham ($P = 0.057$). These data indicate that repeated left DLPFC rTMS reduces the pain severity in a model of prolonged muscle pain. The findings may have implications for the development of sustained pain in clinical populations.

Keywords: Pain, Repetitive transcranial magnetic stimulation, Nerve growth factor, Brain stimulation, Transition

1. Introduction

Musculoskeletal pain disorders are the largest contributors to global years lived with disability.[23] Consequently, effective and affordable strategies are urgently required to deal with this rising problem.

Our previous work has demonstrated disruption of brain cognitive networks with acute pain and with chronic pain,[12,13,31,35,37,38] and we further proposed a role for cognitive network dysfunction in chronic pain disorders and possible treatments.[34] The dorsolateral prefrontal cortex (DLPFC)—particularly the left DLPFC–has been implicated in pain experience and modulation and could be a major node mediating the interaction between pain and cognition.[36] For example, patients have shown altered abnormal cognitive-related activity in the left DLPFC when performing conflict tasks such as the attention network test.[31,38] This suggests that targeting DLPFC function could have effects on both pain and cognitive function, as well as their interaction.

Repetitive transcranial magnetic stimulation (rTMS) of the left DLPFC has been used with some success for the treatment of chronic pain conditions including migraine,[11] burning mouth syndrome,[47] post-traumatic headache,[27] postoperative pain,[8,9] and fibromyalgia where analgesic effects were similar to those of Food and Drug Administration–approved pharmaceuticals with fewer side effects.[30] Left DLPFC rTMS has an immediate analgesic effect for prolonged capsaicin-induced pain in healthy subjects, and the mechanisms of action seem to depend on widespread cortical network effects and activation of the endogenous opioid system.[45,46] Left DLPFC rTMS also modulates dopaminergic[14] and serotonergic systems,[39] which could also potentially modulate pain. Right DLPFC rTMS analgesia does not involve an endogenous opioid mechanism[17] and might be related to glutamatergic modulation.[16] Left–but not right–DLPFC rTMS reduced bilateral capsaicin pain intensity when delivered 10 to 20 minutes after capsaicin application, and the analgesic effects was found after 20 to 30 minutes.[10,45,46] In line with this finding, left DLPFC rTMS increased heat pain thresholds and reduced heat hyperalgesia by capsaicin, but had no effect on cold pain thresholds.[46] Left DLPFC rTMS has also been shown to reverse motor cortex inhibition during capsaicin-induced pain in healthy participants.[22] However, the mechanisms of rTMS for pain are still the subject of considerable

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

[a] Department of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore, MD, United States, [b] Center to Advance Chronic Pain Research, University of Maryland, Baltimore, Baltimore, MD, United States, [c] Department of Health Science and Technology, Center for Neuroplasticity and Pain (CNAP), SMI, The Faculty of Medicine, Aalborg University, Aalborg, Denmark, [d] Brain Rehabilitation and Neuroplasticity Unit (BRAiN-u), Western Sydney University, School of Science and Heath, Sydney, Australia

**Corresponding author. Address: Department of Neural and Pain Sciences, University of Maryland School of Dentistry, 650 W. Baltimore St, 8 South, Baltimore, MD 21201, United States. Tel.: 410 706 3476. E-mail address: dseminowicz@umaryland.edu (D.A. Seminowicz).*

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.painjournalonline.com).

PAIN 159 (2018) 2486–2492

http://dx.doi.org/10.1097/j.pain.0000000000001350

debate,[20] in particular, regarding the timing of rTMS with respect to the nociceptive event, type of pain, and duration of the analgesic effect.

Pain models have been used to study the effects of pain lasting minutes to hours (eg, topical capsaicin) in healthy participants. However, to understand the development of sustained muscle pain, longer-lasting prolonged pain models are needed. Intramuscular injections of nerve growth factor (NGF) induce deep-tissue pain and hyperalgesia for days to weeks[1,4,44] with motor cortical adaptations.[25,33]

In this study, we randomized healthy subjects to receive left DLPFC rTMS over 5 days or sham rTMS to test whether rTMS could reduce pain intensity and distribution, as well as improve cognitive task performance, in a long-lasting (up to 14 days) model of NGF-induced muscle pain. We hypothesized that left DLPFC rTMS would reduce prolonged muscle pain and improve performance on a cognitive task, relative to sham.

2. Materials and methods

2.1. Participants

Thirty healthy right-handed subjects (18 female; 12 male) participated in this randomized controlled study, recruited through online advertising and flyers posted at Aalborg University. All participants were naive to single pulse and rTMS before enrolment and had no history of chronic pain, neurological disorders, and psychiatric disorders. Fifteen participants (9 women for each group) were randomly assigned to each of the active or sham rTMS groups. Inclusion criteria: healthy men and women aged 21 to 50 years; speak and understand English. Exclusion criteria: pregnancy; drug addiction defined as the use of cannabis, opioids, or other drugs; previous neurologic, musculoskeletal, or mental illnesses; lack of ability to cooperate; history of chronic pain or current acute pain; previous experience with rTMS; contraindications to rTMS application (history of epilepsy, metal in the head or jaw, etc.); and failure to pass the Transcranial Magnetic Stimulation Adult Safety Screen (Rossi et al., 2011). Before starting experimental procedures, a physical examination was performed to check the presence of full pain-free range of elbow and wrist motion, and the absence of tenderness to palpation of the soft tissues in the extensor muscles of the wrist. The study was approved by the local Ethics Committee (N-20170041) and was performed in accordance with the Helsinki Declaration. Written informed consent was obtained before study commencement.

2.2. Study protocol

The study involved 6 sessions on 6 consecutive days (day 0-5), plus online daily diaries completed up to day 14. Randomization occurred on day 0 before any assessments. Randomization was based on a predetermined, randomly generated order. Questionnaires were collected at the beginning of the sessions on days 0 and 5. Other data collected as part of the protocol that will be reported elsewhere include motor-evoked potentials, somatosensory-evoked potentials, electroencephalography during cognitive task performance, quantitative sensory, and motor assessment (pressure pain thresholds and wrist extensor force). On day 0 and 2, participants received an injection of NGF into the right extensor radialis carpi brevis (ECRB) muscle to develop muscle pain along the radial site of the right forearm. After assessments at day 0, 1, 2, 3, and 4, participants received 20 minutes of active or sham high-frequency rTMS on the DLPFC. On day 0 and 2, the real or sham rTMS occurred before the NGF injection.

2.3. Questionnaires

At day 0 and day 5, participants completed the following questionnaires: (1) State-Trait Anxiety Inventory (STAI-S, STAI-T)[41]; (2) Pain Catastrophizing Scale[42,43]; (3) Beck Depression Inventory[3]; and (4) Positive and Negative Affective Schedule.[15,48]

The area of pain was assessed using body chart drawings at days 1 to 5, 9, and 14.[40] Participants drew the distribution of their NGF-induced pain on an anatomical drawing of the upper limb. The areas of the body chart drawings were calculated in arbitrary units (a.u.) using a scanning program (VistaMetrix, v.1.38.0; SkillCrest, LLC, Tucson, AZ).

Online diaries regarding muscle soreness and pain severity were completed on days 0 to 14. Muscle soreness was assessed using a modified 7-point Likert scale; 0 = "a complete absence of soreness," 1 = "a light soreness in the muscle felt only when touched/vague ache," 2 = "a moderate soreness felt only when touched/a slight persistent ache," 3 = "a light muscle soreness when lifting or carrying objects," 4 = "a light muscle soreness, stiffness, or weakness when moving the wrist without gripping an object," 5 = "a moderate muscle soreness, stiffness, or weakness when moving the wrist," 6 = "a severe muscle soreness, stiffness, or weakness that limits the ability to move." Pain severity was assessed on a 11-point Numerical Rating Scale (NRS) (0 = no pain and 10 = most intense pain imaginable). The Patient-rated Tennis Elbow Evaluation Questionnaire (PRTEEQ[29]) used to assess average pain and disability of the injected arm, was completed on days 0, 3, 5, 9, and 14.

2.4. Repetitive transcranial magnetic stimulation procedures

Repetitive transcranial magnetic stimulation was delivered using a figure-of-eight–shaped coil (70-mm Double Air Film Coil; Magstim Super Rapid2 Plus1, Magstim Co, Ltd, Dyfed, United Kingdom). The rTMS protocol consisted of 1 session per day for 5 consecutive days. Each 20-minute stimulation session consisted of 80 trains of 5-second pulses with a frequency of 10 Hz and an interval of 10 seconds between each train, giving a total of 4000 pulses per day.[46] The stimulation intensity was 110% of the resting motor threshold (rMT) of the first dorsal interosseous muscle, and the coil was located according to the BeamF3 algorithm.[2,32] The BeamF3 algorithm takes as input 3 scalp measurements: the nasion–inion distance, the left tragus–right tragus distance through the scalp vertex, and the head circumference measured through the FPz-Oz plane in the international 10 to 20 EEG system. These values were entered into the freely available BeamF3 desktop application (clinicalresearcher.org/software.htm) to generate the coordinates to locate the rTMS coil. Sham stimulation was performed with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil (70-mm double air film sham coil). Procedures and instructions to participants in the rTMS and sham groups were identical. Because the rTMS procedure is known to be painful, pain ratings were acquired at the end of each rTMS/sham session,[7] using a 0 to 10 NRS for pain intensity, where 0 was no pain and 10 was most intense pain imaginable.

2.5. Nerve growth factor–induced muscle soreness

Muscle pain and hyperalgesia were induced by repeated injection of NGF into the ECRB muscle, which models lateral

epicondylalgia.[4] Sterile solutions of recombinant human beta-NGF were prepared by the pharmacy (Skanderborg Apotek, Skanderborg, Denmark). Nerve growth factor injections occurred on day 0 and 2. The site of injection was cleaned with alcohol, and NGF solution (5 μg/0.5 mL) was injected into the muscle belly of ECRB, guided in-plane under real-time ultrasound guidance (SonoSite M-Turbo; FUJIFILM SonoSite, Inc).

2.6. Cognitive task

Participants performed the Attention Networks Test[21] on day 0 and 5. This task assesses cognitive function in 3 domains: alerting, orienting, and executive function (conflict resolution). Participants performed the task in 6 blocks of 5 minutes according to the procedure previously reported.[21] Briefly, the task implemented in E-prime (version 3.0) involves the presentation of an arrow, and the correct response is the direction of that arrow, indicated by the button on the participant's right-hand middle (right) or index (left) finger. Around the arrow, 2 arrows can be presented on each side, which can point in the same direction (congruent) or opposite direction (incongruent) of the center target arrow. Additional cues are given before the target stimuli and are related to alerting in orienting. Reaction times were used as the performance measure in the task. Only the conflict (difference between congruent and incongruent reaction time) was examined because these measures previously have been reported in the context of acute and chronic pain,[31,37,38] where increased brain resources have been shown to be recruited.

2.7. Statistical analysis

All data are presented as mean and SEM. All data from all assessments were normality tested using visual inspection and the Shapiro–Wilk test. A mixed-model analysis of variance was used for all parameters to assess effects of day (days 0-14 for muscle soreness and pain intensity, and days 0, 5, 9, and 14 for other measures), group (rTMS and sham), and day-by-group interaction, where the factor day was repeated-measures, and group was between group comparisons. For procedural NRS pain scores, a 1-way repeated-measure analysis of variance was used with time as main factor. We further tested the association between procedural pain and muscle soreness and pain intensity the next day using Pearson correlations. Correcting against violations of sphericity, the Greenhouse–Geisser approach was used. Effect sizes (partial eta-squared [η_p^2]) are reported for significant effects. Where appropriate, post hoc analyses were performed using Bonferroni multiple comparison tests. Statistical significance was set at $P < 0.05$.

3. Results

3.1. Demographics

The sample sizes, sex, age, height, and weight for the sham and active groups are shown in **Table 1**. Groups were matched for sex (6 men and 9 women in each group). All subjects performed all sessions, and no data were missing. Resting motor threshold assessed on days 0 and 5 were (mean ± SD) sham day 0, 42.9 ± 10.0, sham day 5, 41.7 ± 8.7, active day 0, 42.9 ± 11.0, and active day 5, 43.9 ± 9.6.

3.2. Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation reduced pain and muscle soreness

Mean values and SDs for all outcomes are reported in Supplementary Table S1 (available at http://links.lww.com/PAIN/A636). The rTMS group had lower muscle soreness ratings (group main effect: $F_{1,28} = 8.8$, $P = 0.006$, $\eta_p^2 = 0.24$; group-by-time interaction: $F_{4.1,392} = 4.5$, $P = 0.002$, $\eta_p^2 = 0.14$, **Fig. 1A**) and pain intensity NRS ratings (group main effect: $F_{1,28} = 6.3$, $P = 0.018$, $\eta_p^2 = 0.19$; group-by-time interaction: $F_{2.9,392} = 2.5$, $P = 0.068$, $\eta_p^2 = 0.09$, **Fig. 1B**) than the sham group. Post hoc tests revealed that differences in muscle soreness Likert scores were apparent at 2, 4, 5, 6, and 7 days after the first NGF injection, ($P < 0.05$). Because these Likert score data were non-normally distributed, we also performed Kruskal–Wallis tests and found the same as the parametric tests (ie, days 2, 4, 5, 6, and 7 were different between groups). The rTMS group also had a similar, but nonsignificant trend toward reduced disability as assessed by the Patient-rated Tennis Elbow Evaluation Questionnaire, which was apparent by day 5 (group main effect: $F_{1,28} = 2.5$, $P > 0.1$, $\eta_p^2 = 0.08$; and group-by-time interaction: $F_{1.4,112} = 2.1$, $P > 0.1$, $\eta_p^2 = 0.07$, **Fig. 1C**).

Table 1

Participant characteristics.

	Active rTMS group		Sham rTMS group	
Sample size	15		15	
Sex (M, F)	6, 9		6, 9	
Age (y)	26.9 ± 1.0		26 ± 1.4	
Height (cm)	170 ± 2.2		172 ± 2.9	
Weight (kg)	69 ± 3.5		75 ± 4.7	
	Day 0	Day 5	Day 0	Day 5
Depression (BDI-II)	5.7 ± 1.6	5.1 ± 1.4	7.2 ± 2.3	7.4 ± 2.6
State anxiety (STAI-S)	42.0 ± 1.4	41.3 ± 1.6	40.5 ± 1.2	40.6 ± 1.6
Trait anxiety (STAI-T)	47.2 ± 0.8	46.5 ± 1.1	46.5 ± 1.3	46.6 ± 1.0
Pain Catastrophizing Scale	15.8 ± 2.3	12.6 ± 2.5	11.9 ± 2.2	11.6 ± 2.3
PANAS-negative	12.7 ± 0.6	12.2 ± 0.5	11.5 ± 0.5	11.3 ± 0.5
PANAS-positive	28.1 ± 2.2	26.9 ± 2.8	26.1 ± 2.1	28.7 ± 2.5

BDI-II, beck depression inventory; PANAS, positive and negative affective schedule; rTMS, repetitive transcranial magnetic stimulation; STAI, state-trait anxiety inventory.



Figure 1. Mean (±SEM, N = 15) Likert scores of muscle soreness (A), pain intensity NRS scores (B), Patient-rated Tennis Elbow Evaluation Questionnaire (PRTEEQ) scores (C), and pain area (body map) (D) after NGF injections on day 0 and day 2 in groups receiving active and sham rTMS. Note that rTMS occurred on days 0, 1, 2, 3, and 4. *Significant Bonferroni-corrected post hoc tests for analyses with significant group-by-time interactions ($P < 0.05$). ŦSignificant main effect of group. NGF, nerve growth factor; NRS, Numerical Rating Scale; rTMS, repetitive transcranial magnetic stimulation.

Area of pain based on body map drawings was lower in the real rTMS compared with sham group (group main effect: $F_{1,28} = 9.6$, $P = 0.004$, $\eta_p^2 = 0.26$; and group-by-time interaction: $F_{3.4,168} = 4.1$, $P = 0.006$, $\eta_p^2 = 0.13$, **Fig. 1D**), and post hoc tests indicated significant differences at days 3 and 5 ($P < 0.05$).

3.3. Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation showed a trend toward improved cognitive task performance

The rTMS group had a marginally greater reduction in conflict cost (ie, improved performance in reaction time) compared with sham at day 5 compared with baseline (group main effect: $F_{1,28} = 1.1$, $P > 0.2$, $\eta_p^2 = 0.04$; group-by-time interaction: $F_{1,28} = 3.9$, $P = 0.057$, $\eta_p^2 = 0.12$). This represented a conflict reaction time cost reduction from 96.5 ± 6.8 milliseconds at baseline to 74.8 ± 4.2 milliseconds at day 5 in the rTMS group, vs a reduction from 97.4 ± 4.9 milliseconds to 89.9 ± 7.1 milliseconds in the sham group. There were no differences between rTMS and sham groups on the alerting (41.7 ± 4.1 milliseconds at baseline to 49.4 ± 5.3 at day 5 for rTMS group vs 34.8 ± 6.3 milliseconds at baseline to 46.1 ± 7.1 at day 5 for sham group; group main effect: $F_{1,28} = 0.5$, $P > 0.5$; group-by-time interaction: $F_{1,28} = 0.2$, $P > 0.5$) and orienting components of the task (27.3 ± 3.7 milliseconds at baseline to 25.6 ± 4.3 at day 5 for rTMS group vs 33.5 ± 5.8 milliseconds at baseline to 29.2 ± 3.6 at day 5 for sham group; group main effect: $F_{1,28} = 0.9$, $P > 0.3$; group-by-time interaction: $F_{1,28} = 0.1$, $P > 0.5$).

3.4. No effects of left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on anxiety, depression, affect, or pain catastrophizing

There was no difference between groups in terms for state anxiety (group main effect: $F_{1,28} = 0.3$, $P > 0.5$; group-by-time interaction: $F_{1,28} = 0.3$, $P > 0.5$) or trait anxiety (group main effect: $F_{1,28} = 0.05$, $P > 0.5$; group-by-time interaction: $F_{1,28} = 0.4$, $P > 0.5$), depression (group main effect: $F_{1,28} = 0.4$, $P > 0.5$; group-by-time interaction: $F_{1,28} = 0.9$, $P > 0.3$), pain catastrophizing (group main effect: $F_{1,28} = 1.2$, $P > 0.2$; group-by-time interaction: $F_{1,28} = 0.6$, $P > 0.4$), or positive affect (group main effect: $F_{1,28} = 0.003$, $P > 0.5$; group-by-time interaction: $F_{1,28} = 1.2$, $P > 0.2$) or negative affect (group main effect: $F_{1,28} = 3.0$, $P > 0.1$; group-by-time interaction: $F_{1,28} = 0.1$, $P > 0.5$) on the Positive and Negative Affective Schedule. These characteristics are reported in **Table 1**.

3.5. Repetitive transcranial magnetic stimulation procedural pain

The rTMS intensity used in this study was 60.1 ± 2.5. Procedural NRS pain ratings and rTMS intensity correlated (Pearson $r = 0.56$, $P < 0.05$). Procedural NRS pain ratings steadily decreased across days, from 5.6 ± 0.8 on day 0 to 4.2 ± 0.7, 3.8 ± 0.6, 3.5 ± 0.6, and 2.9 ± 0.6 for days 1 through 4, respectively ($F_{1.87,52} = 8.8$, $P = 0.002$, $\eta_p^2 = 0.40$), indicating that pain was reduced over time, consistent with previous reports. Furthermore, Pearson correlations revealed no relevant relationship between lower NGF

pain with higher procedural pain the previous day. The sham procedure was never painful. No side effects were reported, and the treatment was well-tolerated by all participants.

4. Discussion

The present results show that 5 days of treatment with left DLPFC high-frequency (excitatory) rTMS can reduce the pain intensity, distribution, and muscle soreness associated with long-lasting experimental muscle pain. Moreover, no significant effect on depression, anxiety, pain catastrophizing, or affect scores was found because of rTMS, although a near-significant improvement in cognitive task performance was observed. The NGF-induced muscle pain model is believed to closely reflect the period of acute pain before the transition to chronic pain.[4,33] Because pain intensity is a strong predictor of the transition to chronic pain,[26] interventions such as left DLPFC rTMS that reduce pain during the early periods of development have the potential clinical application of preventing the persistent pain after injury or surgery.

4.1. Effects of dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on pain

The mechanisms by which left DLPFC rTMS produce analgesia are yet unclear, but growing evidence points to the left DLPFC as an important region in pain experience and modulation.[36] Although one study has shown that left DLPFC rTMS reduces postoperative pain, the stimulation was performed after surgery.[8] It has yet to be tested whether rTMS before surgery can prevent the development of acute and chronic pain. Left DLPFC rTMS has shown promise for a number of chronic pain conditions, including migraine,[11] post-traumatic headache,[27] fibromyalgia,[30] and burning mouth syndrome;[47] although for central poststroke pain, it has been shown to be ineffective.[18] Left DLPFC rTMS could thus be an effective treatment for pain or pain prevention. In the current study, effects of rTMS were strongest on the later days of intervention and 3 days afterward (ie, days 2-7), whereas minimal differences between active and sham groups were seen late (ie, days 8-14). Further studies using DLPFC rTMS are required to determine whether a longer intervention period would have longer-lasting effects. One mechanism of left DLPFC rTMS analgesia could be activation of the descending modulatory endogenous opioidergic system,[45,46] although the involvement of glutamatergic, dopaminergic, and serotonergic systems is also plausible.[14,16,39]

High-frequency rTMS of the left DLPFC is an effective treatment for major depressive disorder.[24] The effects on mood present another means by which left DLPFC rTMS could have analgesic effects.[5,6,27,49] We found no effect of left DLPFC rTMS on positive or negative affect, anxiety, or depression, which could have been a result of either the low scores on these questionnaires given the healthy participants involved, or the shorter period of intervention compared with typical clinical protocols for depression (weeks).

4.2. Effects of dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on cognitive function

Another possibility is that the analgesic effects derived from left DLPFC rTMS occur through modulation of cognitive function.[34,36] Previous work has shown the left DLPFC stimulation can modulate cognitive function. For example, a recent study reported that transcranial direct current stimulation over the left DLPFC improved performance on a working memory task, which was also associated with a reduction in simultaneous pain evoked with an electrical stimulus.[19] Improved performance on a Stroop task was also reported after 7 days of high frequency left DLPFC rTMS.[28] We therefore assessed cognitive function on a similar cognitive task involving cognitive conflict and found that left DLPFC rTMS was associated with an improvement in cognitive task performance compared with sham, although this effect failed to reach statistical significance, possibly because the stimulation was not repeated for enough days or the sample size was too small. Previous work has shown that in chronic pain conditions, cognitive-related activation of the left DLPFC is increased relative to healthy controls,[31,38] and after treatment, activation and connectivity of the left DLPFC normalizes.[13,38] Although the relationship between left DLPFC function and pain is unclear, more extensive follow-up studies on the interaction between DLPFC stimulation, cognitive function, and pain are warranted.

4.3. Limitations

There were some notable limitations to the study. First, although our sample size was greater than in previous studies on left DLPFC rTMS for acute[46] or chronic[47] pain, it was fairly small. Although the main outcomes of the study were significant, others, such as disability and cognitive function, showed a nonsignificant trend. These effects are likely to reach significance with a slightly larger sample. Second, as has been reported previously, DLPFC rTMS is painful.[7] We observed similar procedural pain intensity and decrease in procedural pain over time as previously reported.[7,47] This reduction over time has been interpreted as an analgesic effect of the rTMS rather than habituation to the stimulation over time because the sham procedural pain evoked with electrical stimulation below the sham coil in that study did not show a change over time.[7] In addition, because our measures of pain related to the NGF were acquired a day after intervention, it seems unlikely that differences between sham and rTMS would be related to procedural pain. Another possible limitation is that the stimulation we used was at 110% of the baseline rMT, rather than reacquiring rMT at each session. This is similar to other protocols.[28] Although rMT is likely to change with the NGF model, whether this affects DLPFC response is unknown. A final limitation is that the study was single blind: although participants did not know whether they received real or sham rTMS, the experimenter involved in data collection was not blinded.

5. Conclusion

Five days of left DLPFC rTMS reduced the development of ongoing pain induced by an NGF muscle pain model compared with the sham rTMS. These changes lasted at least 3 days after the intervention period and occurred in the absence of changes in mood, affect, anxiety, or pain catastrophizing. A trend of improved cognitive performance was also seen in active compared with sham rTMS. Overall, this study provides early evidence for the use of left DLPFC rTMS for preventing the development of pain shortly after tissue trauma.

Conflict of interest statement

The authors have no conflict of interest to declare.

This study was performed at Center for Neuroplasticity and Pain (CNAP), which is supported by the Danish National Research Foundation (DNRF121). S.M. Schabrun receives salary

support from The National Health and Medical Research Council of Australia (1105040).

Appendix A. Supplemental digital content

Supplemental digital content associated with this article can be found online at http://links.lww.com/PAIN/A636.

Article history:
Received 9 May 2018
Received in revised form 1 July 2018
Accepted 17 July 2018
Available online 20 July 2018

References

[1] Andersen H, Arendt-Nielsen L, Svensson P, Danneskiold-Samsoe B, Graven-Nielsen T. Spatial and temporal aspects of muscle hyperalgesia induced by nerve growth factor in humans. Exp Brain Res 2008;191: 371–82.
[2] Beam W, Borckardt JJ, Reeves ST, George MS. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimul 2009;2:50–4.
[3] Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.
[4] Bergin MJ, Hirata R, Mista C, Christensen SW, Tucker K, Vicenzino B, Hodges P, Graven-Nielsen T. Movement evoked pain and mechanical hyperalgesia after intramuscular injection of nerve growth factor: a model of sustained elbow pain. Pain Med 2015;16:2180–91.
[5] Berna C, Leknes S, Holmes EA, Edwards RR, Goodwin GM, Tracey I. Induction of depressed mood disrupts emotion regulation neurocircuitry and enhances pain unpleasantness. Biol Psychiatry 2010;67:1083–90.
[6] Boettger MK, Schwier C, Bar KJ. Sad mood increases pain sensitivity upon thermal grill illusion stimulation: implications for central pain processing. PAIN 2011;152:123–30.
[7] Borckardt JJ, Nahas ZH, Teal J, Lisanby SH, McDonald WM, Avery D, Durkalski V, Pavlicova M, Long JM, Sackeim HA, George MS. The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial. Brain Stimul 2013;6:925–8.
[8] Borckardt JJ, Reeves ST, Kotlowski P, Abernathy JH, Field LC, Dong L, Frohman H, Moore H, Ryan K, Madan A, George MS. Fast left prefrontal rTMS reduces post-gastric bypass surgery pain: findings from a large-scale, double-blind, sham-controlled clinical trial. Brain Stimul 2014;7: 42–8.
[9] Borckardt JJ, Reeves ST, Weinstein M, Smith AR, Shelley N, Kozel FA, Nahas Z, Byrne KT, Morgan K, George MS. Significant analgesic effects of one session of postoperative left prefrontal cortex repetitive transcranial magnetic stimulation: a replication study. Brain Stimul 2008;1:122–7.
[10] Brighina F, De TM, Giglia F, Scalia S, Cosentino G, Puma A, Panetta M, Giglia G, Fierro B. Modulation of pain perception by transcranial magnetic stimulation of left prefrontal cortex. J Headache Pain 2011;12:185–91.
[11] Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci 2004;227:67–71.
[12] Ceko M, Gracely JL, Fitzcharles MA, Seminowicz DA, Schweinhardt P, Bushnell MC. Is a responsive default mode network required for successful working memory task performance? J Neurosci 2015;19: 11595–605.
[13] Ceko M, Shir Y, Ouellet JA, Ware MA, Stone LS, Seminowicz DA. Partial recovery of abnormal insula and dorsolateral prefrontal connectivity to cognitive networks in chronic low back pain after treatment. Hum Brain Mapp 2015;36:2075–92.
[14] Cho SS, Strafella AP. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 2009;4:e6725.
[15] Crawford JR, Henry JD. The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol 2004;43:245–65.
[16] de Andrade DC, Mhalla A, Adam F, Texeira MJ, Bouhassira D. Repetitive transcranial magnetic stimulation induced analgesia depends on N-methyl-D-aspartate glutamate receptors. PAIN 2014;155:598–605.
[17] de Andrade DC, Mhalla A, Adam F, Texeira MJ, Bouhassira D. Neuropharmacological basis of rTMS-induced analgesia: the role of endogenous opioids. PAIN 2011;152:320–6.
[18] de Oliveira RA, de Andrade DC, Mendonca M, Barros R, Luvisoto T, Myczkowski ML, Marcolin MA, Teixeira MJ. Repetitive transcranial magnetic stimulation of the left premotor/dorsolateral prefrontal cortex does not have analgesic effect on central poststroke pain. J Pain 2014; 15:1271–81.
[19] Deldar Z, Rustamov N, Bois S, Blanchette I, Piche M. Enhancement of pain inhibition by working memory with anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex. J Physiol Sci 2018. doi: 10.1007/s12576-018-0598-4 [e-pub ahead of print].
[20] DosSantos MF, Ferreira N, Toback RL, Carvalho AC, DaSilva AF. Potential mechanisms supporting the value of motor cortex stimulation to treat chronic pain syndromes. Front Neurosci 2016;10:18.
[21] Fan J, Gu X, Guise KG, Liu X, Fossella J, Wang H, Posner MI. Testing the behavioral interaction and integration of attentional networks. Brain Cogn 2009;70:209–20.
[22] Fierro B, De TM, Giglia F, Giglia G, Palermo A, Brighina F. Repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex (DLPFC) during capsaicin-induced pain: modulatory effects on motor cortex excitability. Exp Brain Res 2010;203:31–8.
[23] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–59.
[24] George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry 2013;26:13–18.
[25] Hayashi K, Shiozawa S, Ozaki N, Mizumura K, Graven-Nielsen T. Repeated intramuscular injections of nerve growth factor induced progressive muscle hyperalgesia, facilitated temporal summation, and expanded pain areas. PAIN 2013;154:2344–52.
[26] Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother 2009;9:723–44.
[27] Leung A, Metzger-Smith V, He Y, Cordero J, Ehlert B, Song D, Lin L, Shahrokh G, Tsai A, Vaninetti M, Rutledge T, Polston G, Sheu R, Lee R. Left dorsolateral prefrontal cortex rTMS in alleviating MTBI related headaches and depressive symptoms. Neuromodulation 2018;21: 390–401.
[28] Li Y, Wang L, Jia M, Guo J, Wang H, Wang M. The effects of high-frequency rTMS over the left DLPFC on cognitive control in young healthy participants. PLoS One 2017;12:e0179430.
[29] Macdermid J. Update: the patient-rated forearm evaluation questionnaire is now the patient-rated tennis elbow evaluation. J Hand Ther 2005;18: 407–10.
[30] Marlow NM, Bonilha HS, Short EB. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. Pain Pract 2013;13: 131–45.
[31] Mathur VA, Khan SA, Keaser ML, Hubbard CS, Goyal M, Seminowicz DA. Altered cognition-related brain activity and interactions with acute pain in migraine. Neuroimage Clin 2015;7:347–58.
[32] Mir-Moghtadaei A, Caballero R, Fried P, Fox MD, Lee K, Giacobbe P, Daskalakis ZJ, Blumberger DM, Downar J. Concordance between BeamF3 and MRI-neuronavigated target sites for repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex. Brain Stimul 2015;8:965–73.
[33] Schabrun SM, Christensen SW, Mrachacz-Kersting N, Graven-Nielsen T. Motor cortex reorganization and impaired function in the transition to sustained muscle pain. Cereb Cortex 2016;26:1878–90.
[34] Seminowicz DA, Ceko M. Can we exploit cognitive brain networks to treat chronic pain? Pain Manag 2015;5:399–402.
[35] Seminowicz DA, Mikulis DJ, Davis KD. Cognitive modulation of pain-related brain responses depends on behavioral strategy. PAIN 2004;112: 48–58.
[36] Seminowicz DA, Moayedi M. The dorsolateral prefrontal cortex in acute and chronic pain. J Pain 2017;18:1027–35.
[37] Seminowicz DA, Davis KD. Pain enhances functional connectivity of a brain network evoked by performance of a cognitive task. J Neurophysiol 2007;97:3651–9.
[38] Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA, Jarzem P, Bushnell MC, Shir Y, Ouellet JA, Stone LS. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J Neurosci 2011;31:7540–50.
[39] Sibon I, Strafella AP, Gravel P, Ko JH, Booij L, Soucy JP, Leyton M, Diksic M, Benkelfat C. Acute prefrontal cortex TMS in healthy volunteers: effects on brain 11C-alphaMtrp trapping. Neuroimage 2007;34:1658–64.
[40] Slater H, Arendt-Nielsen L, Wright A, Graven-Nielsen T. Experimental deep tissue pain in wrist extensors–a model of lateral epicondylalgia. Eur J Pain 2003;7:277–88.

[41] Spielberger CD, Gorsuch RL, Lushene RE. STAI: Manual for the State–Trait Anxiety Inventory (STAI). Palo Alto: Consulting Psychologists Press, 1970.
[42] Sullivan MJ, Stanish W, Waite H, Sullivan M, Tripp DA. Catastrophizing, pain, and disability in patients with soft-tissue injuries. PAIN 1998;77:253–60.
[43] Sullivan MJ, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32.
[44] Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. PAIN 2003;104:241–7.
[45] Taylor JJ, Borckardt JJ, Canterberry M, Li X, Hanlon CA, Brown TR, George MS. Naloxone-reversible modulation of pain circuitry by left prefrontal rTMS. Neuropsychopharmacology 2013;38:1189–97.
[46] Taylor JJ, Borckardt JJ, George MS. Endogenous opioids mediate left dorsolateral prefrontal cortex rTMS-induced analgesia. PAIN 2012;153:1219–25.
[47] Umezaki Y, Badran BW, DeVries WH, Moss J, Gonzales T, George MS. The efficacy of daily prefrontal repetitive transcranial magnetic stimulation (rTMS) for burning mouth syndrome (BMS): a randomized controlled single-blind study. Brain Stimul 2016;9:234–42.
[48] Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063–70.
[49] Zelman DC, Howland EW, Nichols SN, Cleeland CS. The effects of induced mood on laboratory pain. PAIN 1991;46:105–11.